Astellas To Set Up Branch Office In Chengdu
This article was originally published in PharmAsia News
Executive Summary
Japanese drug R&D corporation Astellas, ranked 35th on the Fortune 500 list in 2008, will establish a branch office in Chengdu to handle business in southwest and northwest China. The new office will be in charge of marketing promotion in the western region, along with bringing the world's most updated drug information, healthcare developments and market trends to hospitals and doctors. Depending on the market situation, the firm does not rule out the possibility of setting up a pharmaceutical plant or R&D center in the city. Texas Instruments is another Fortune 500 company setting up a base in Chengdu. (Click here for more - Chinese Language)
You may also be interested in...
Astellas Forecasts Earnings Decline; Says Urology Franchise Will Drive Global Growth
Astellas recently reported declining sales, operating income and profits for fiscal year 2008 due to the appreciation of the yen and the revision of Japan's drug pricing policy. The decline in sales and earnings was the first to be posted since the 2005 merger between Fujisawa and Yamanouchi Pharmaceutical
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.